None listed
Conditions
Interventions
None listed
Sponsors
Daiichi-Sankyo Korea
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with atrial fibrillation who were prescribed a non-vitamin K antagonist oral anticoagulant (NOAC) for the first time between January 1, 2016, and September 30, 2023. *The index date is defined as the first prescription date of a NOAC. 2) Patients with a prescription for olmesartan or telmisartan within 60 days, including the index date. 3) Patients who are at least 19 years old at the index date. 4) Patients with at least one year of prior medical utilization records before the index date.
Exclusion criteria
Exclusion criteria: 1) Patients prescribed an oral anticoagulant other than a non-vitamin K antagonist oral anticoagulant (NOAC) at the index date. 2) Patients diagnosed with valvular atrial fibrillation at any time, including the index date and prior periods. 3) Patients diagnosed with end-stage renal disease (ESRD) at any time, including the index date and prior periods. 4) Patients diagnosed with pulmonary embolism (PE) or deep vein thrombosis (DVT) or who underwent hip replacement surgery within six months prior to or on the index date. 5) Patients diagnosed with intracranial hemorrhage, gastrointestinal bleeding, or ischemic stroke at any time, including the index date and prior periods. 6) Patients prescribed an angiotensin receptor blocker (ARB) other than olmesartan or telmisartan within 60 days before or on the index date.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of intracranial hemorrhage or gastrointestinal bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| intracranial hemorrhage;Gastrointestinal bleeding;Ischemic stroke;All-cause death;Net adverse clinical events | — |
Countries
Korea, Republic of
Contacts
Public ContactSeng Chan You
Yonsei University
Outcome results
None listed